Project Grant R01CA305975
Award Date 7/6/26
Completion Date 6/30/31
Dollars Obligated $713K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Cancer Institute (NCI) awarded $624,194 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, for a five-year project completing March 31, 2031. This Project Grant supports fundamental cancer immunology research investigating how the Integrated Stress Response (ISR) regulates CD8+ tumor-infiltrating lymphocyte (TIL) function and metabolic homeostasis in hypoxic tumor microenvironments. The research focuses on...
- Federal Grant Award Summary The National Cancer Institute awards $653,846 to the University of North Carolina at Chapel Hill under the Cancer Treatment Research program (CFDA 93.395) for a five-year project period (July 1, 2026 – June 30, 2031). This Project Grant supports the development of novel cancer therapeutics through targeted protein degradation (TPD), an emerging therapeutic strategy designed to move beyond traditional pharmacology by recruiting proteins of interest to cellular...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $769,260 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded April 10, 2026, with completion targeted for March 31, 2028. This research initiative aims to identify immune-mediated mechanisms underlying the efficacy and resistance of RAS inhibitors in pancreatic ductal adenocarcinoma (PDAC). The project delivers fundamental cancer biology...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $150,784 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of North Carolina at Charlotte, effective September 1, 2025, through August 31, 2027. This two-year research initiative investigates the interplay between Heat Shock Protein 70 (HSP70) chaperone function and cyclin D1/CLN3 cell cycle regulation, with direct implications for cancer therapeutics. The research focuses on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $658,423 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026 through June 30, 2031. This award supports fundamental research on therapeutic targeting of PI3K gamma (PI3Kγ)-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC) to reduce health disparities. The research builds on the investigator...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...